Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413061 · ClinicalTrials.gov registry record · NA
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
A NA study, sponsored by AlloSource.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT01413061: Completed NA study, sponsored by AlloSource.
NCT01413061 is a NA study that has completed, run by AlloSource. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01413061, a NA study, has completed, sponsored by AlloSource.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to evaluate the outcome of implanting AlloStem® graft with appropriate rigid internal fixation hardware as an alternative to autograft bone graft with rigid fixation in subtalar arthrodesis procedures. The primary objective of this clinical trial is to compare the overall fusion rate of the investigational to the control treatment. Fusion will be determined by clinical findings, radiographs and computed tomography (CT) of the subtalar joint 24 weeks (6 months) after the trial surgery.
Primary Outcome
Fusion Rate (%)(as determined by CT assessment)
Interventions
- PROCEDURE Subtalar Arthrodesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2010-06 |
| Est. Completion | 2018-03 |
| Phase | NA |
What the finished NCT01413061 record still lists
NCT01413061 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Subtalar Arthrodesis is the first listed.
NCT01413061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01413061 about?
NCT01413061 is a clinical study titled "Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft". The purpose of this clinical trial is to evaluate the outcome of implanting AlloStem® graft with appropriate rigid internal fixation hardware as an alternative to autograft bone graft with rigid fixation in subtalar arthrodesis procedures. The primary objective of this clinical trial is to compare t...
What is the current status of trial NCT01413061?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2010-06. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01413061?
The interventions under investigation include: Subtalar Arthrodesis (PROCEDURE).
Who is sponsoring clinical trial NCT01413061?
This trial is sponsored by AlloSource, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01413061's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia